BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26681761)

  • 1. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
    Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
    Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
    [No Abstract]   [Full Text] [Related]  

  • 2. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
    Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
    Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of a cryptic
    Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
    Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
    Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia.
    Balatzenko G; Guenova M; Kalinova I; Belcheva M; Hristozova H; Kaleva V
    Cancer Genet; 2013 Mar; 206(3):97-101. PubMed ID: 23491079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
    Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
    Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
    Perwein T; Strehl S; König M; Lackner H; Panzer-Grümayer R; Mann G; Attarbaschi A; Urban EC; Haas OA
    Haematologica; 2016 Aug; 101(8):e332-5. PubMed ID: 27125982
    [No Abstract]   [Full Text] [Related]  

  • 8. t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia.
    Sheng G; Zeng Z; Pan J; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
    Acta Haematol; 2017; 137(1):40-43. PubMed ID: 27894117
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with
    Aldoss I; Pullarkat V
    Leuk Lymphoma; 2019 Nov; 60(11):2832-2834. PubMed ID: 31014138
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
    Hu T; Ciccarelli BT
    Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
    [No Abstract]   [Full Text] [Related]  

  • 12. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
    Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
    Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
    Hagemeijer A; Graux C
    Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NUP98 rearrangement in B lymphoblastic leukemia with hyperdiploidy.
    Liu H
    Blood; 2020 Aug; 136(8):1011. PubMed ID: 32818249
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukemia cutis with lymphoglandular bodies: a clue to acute lymphoblastic leukemia cutis.
    Obiozor C; Ganguly S; Fraga GR
    Dermatol Online J; 2015 Aug; 21(8):. PubMed ID: 26437164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
    Burmeister T; Gökbuget N; Reinhardt R; Rieder H; Hoelzer D; Schwartz S
    Blood; 2006 Nov; 108(10):3556-9. PubMed ID: 16873673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
    Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
    Clarke S; O'Reilly J; Romeo G; Cooney J
    Leuk Res; 2011 Jul; 35(7):e131-3. PubMed ID: 21489623
    [No Abstract]   [Full Text] [Related]  

  • 19. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
    Crombet O; Lastrapes K; Zieske A; Morales-Arias J
    Pediatr Blood Cancer; 2012 Aug; 59(2):333-4. PubMed ID: 22689211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.
    Eyre T; Schwab CJ; Kinstrie R; McGuire AK; Strefford J; Peniket A; Mead A; Littlewood T; Holyoake TL; Copland M; Moorman AV; Harrison CJ; Vyas P
    Blood; 2012 Nov; 120(22):4441-3. PubMed ID: 23175662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.